Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120PRNewsWire • 06/05/23
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and ShareholdersBusiness Wire • 05/25/23
MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development StrategyBusiness Wire • 05/25/23
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual MeetingBusiness Wire • 05/24/23
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)Business Wire • 05/17/23
MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker saysProactive Investors • 05/09/23
MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing StrategyBusiness Wire • 05/02/23
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 05/01/23
MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorderMarket Watch • 04/14/23
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)Business Wire • 04/14/23
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate SecretaryBusiness Wire • 04/13/23